Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Chembiochem : a European Journal of Chemical Biology|April 16, 2019
ATP Inhibits the Transcription Factor STAT5bAngela Berg, Bianca Sperl, Thorsten BergOncotarget|November 7, 2014
Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 statusZhiguang Xiao, Bianca Sperl, Axel Ullrich, et al.Bioorganic & Medicinal Chemistry Letters|May 12, 2009
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domainsBianca Sperl, Markus H J Seifert, Thorsten BergNature|December 18, 2015
Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding siteVijay K Ulaganathan, Bianca Sperl, Ulf R Rapp, et al.Chemistry & Biology|July 29, 2006
Selective inhibition of c-Myc/Max dimerization and DNA binding by small moleculesAnke Kiessling, Bianca Sperl, Angela Hollis, et al.Chemistry & Biology|November 23, 2006
Stattic: a small-molecule inhibitor of STAT3 activation and dimerizationJochen Schust, Bianca Sperl, Angela Hollis, et al.Journal of Molecular Recognition : JMR|September 4, 2009
Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptorsAlexander Riechers, Andreas Grauer, Stefan Ritter, et al.Oncotarget|May 10, 2019
Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approachZhiguang Xiao, Bianca Sperl, Silvia Gärtner, et al.Oncotarget|August 26, 2021
Correction: Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approachZhiguang Xiao, Bianca Sperl, Silvia Gärtner, et al.ACS Chemical Biology|July 30, 2011
Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivativesMartin Gräber, Weronika Janczyk, Bianca Sperl, et al.Pageof 2